Fig. 5

Alternate day difluorosamine treatment after ICH promotes functional recovery, reduces neurocan expression and shifts the functional state of microglia/macrophages towards homeostasis over 14 days. A Treatment paradigm of difluorosamine in ICH: 14-day experiment. B, C Bar graphs comparing the latency of rota-rod test (B) or forelimb force of grip strength test (C) between control and DIF mice. D, E Representative confocal images of perihematomal area at day 14 in control (D) and DIF (E) mice stained for neurocan (red), Iba1 (green), GFAP (blue). Scale bar = 50 μm. F Bar graphs comparing neurocan percent area of the lesion region of interest (ROI). G–I Quantification showing the percentage of IL-1β (G), Clec7a (H), Arg1 (I) in lesion ROI between control and DIF mice. Data are presented as the mean ± SEM of 6 mice. Unpaired two-tailed Student’s t-test; Significance indicated as *p < 0.05, **p < 0.01, ***p < 0.001